2025 · 1st Quarter (Jan 1 - Mar 31)

GILEAD SCIENCES, INC.

Filed by TIBER CREEK GROUP.

Open official filing

Source-reported fields

Filing overview

Type: 1st Quarter - Report
Posted: Apr 20, 2025
Income: $50,000.00
Expenses: Not reported
Registrant: TIBER CREEK GROUP
Client: GILEAD SCIENCES, INC.
Filing UUID: 0897e4e5-057a-4dbf-aeef-3e76134c342d
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

TRD · Trade (domestic/foreign)

Issues related to international trade; Issues related to intellectual property protections for COVID-19 treatments; Issues related to the TRIPS Waiver; Global supply chain issues, including S. 998 - Medical Supply Chain Resiliency Act; Issues related to compulsory licensing and other intellectual property issues in multiple countries.

Literal federal measure citations: S. 998

HCR · Health Issues

Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158).

MMM · Medicare/Medicaid

Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158).

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.